Effectiveness of Treatment With Tofacitinib in Patients With Psoriatic Arthritis in Routine Clinical Practice

About the study

This is a Multinational Study of Tofacitinib in Patients Treated for Psoriatic Arthritis in order to evaluate the effectiveness of treatment with tofacitinib on disease activity, remission, and Quality of Life, in a real-world setting over a 12-month observation period

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria: Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:

Patients aged ≥ 18 years
Moderate to severe PsA disease activity diagnosed
Patients for whom the physician's decision has been made to initiate treatment with tofacitinib, in usual clinical practice conditions and in compliance with the local label
Patients are treatment naïve to tofacitinib on the date of providing informed consent
Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study
Patients on DMARDs must have not had a treatment change in the past 3 months

EXCLUSION CRITERIA

Exclusion Criteria: Patients meeting any of the following criteria will not be included in the study:

Contraindications according to the Xeljanz® (tofacitinib) Prescribing Information
Receipt of any investigational drug within 3 months before study inclusion
Patient is pregnant or breastfeeding
Recent herpes zoster infection (within past 6 months) or history of severe disseminated herpes zoster infection
Active treatment for a malignancy
Concomitant treatment with a biological disease-modifying antirheumatic drugs (bDMARD)